Notification spécifique, par un Membre importateur, des renseignements requis dans le cadre du régime de licences obligatoires spéciales ‒ Afficher les détails du document

The following notification from Rwanda's Government Centre for the Treatment & Research on AIDS (TRAC) has been received from the Delegation of Rwanda on 17 July 2007 for circulation to the Council for TRIPS. _______________ Based on Rwanda's present evaluation of its public health needs, we expect to import during the next two years 260,000 packs of TriAvir, a fixed-dose combination product of Zidovudine, Lamivudine and Nevirapine (hereinafter referred to as the "Product") manufactured in Canada by Apotex, Inc. However, because it is not possible to predict with certainty the extent of the country's public health needs, we reserve the right to modify the foregoing estimate as necessary or appropriate. Pursuant to Paragraph 7 of the Doha Declaration and implementation thereof by the TRIPS Council (Decision of the Council for TRIPS of 27 June 2002), we have decided that we will not enforce rights provided under Part II Section 5 of the TRIPS Agreement that may have been granted within Rwanda's territory with respect to the Product.

Liste de produit(s) nécessaire(s)

Nom du produit Quantité du produit  
Il n'y a actuellement aucun élément dans la base de données.
TriAvir, a fixed-dose combination product of Zidovudine, Lamivudine
260,000 packs

Détails de la notification

*Les PMA ne sont pas tenus de choisir une option ci-dessus concernant les capacités de fabrication.